BiotechTube
FGH BioTech

FGH BioTech

San Diego, United States· Est.
fghbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

FGH BioTech is a preclinical-stage biotech leveraging over 60 years of foundational research in fat metabolism to develop first-in-class small molecule inhibitors of SREBP transcription factors. Its platform targets the root metabolic drivers of prevalent conditions like fatty liver disease, diabetes, cardiovascular disease, and aggressive cancers such as castration-resistant prostate cancer. The company is privately held, pre-revenue, and advancing its lead programs through preclinical proof-of-concept, aiming to address multi-billion-dollar markets with high unmet need.

Metabolic DiseasesOncology

Technology Platform

Small molecule drugs targeting SREBP (sterol regulatory element-binding protein) transcription factors and related pathways to regulate lipid metabolism.

Opportunities

The company targets massive, underserved markets in metabolic disease (e.g., NASH, diabetes) and oncology (e.g., castration-resistant prostate cancer) with a novel mechanism.
Success in one area could validate the platform for rapid expansion into the other, creating a diversified pipeline.
A compelling preclinical data package could attract partnership deals with larger pharma companies.

Risk Factors

High risk of preclinical data not translating to human efficacy or safety, given the fundamental role of SREBP in normal physiology.
As a private, early-stage company, it faces significant financing risk and intense competition from well-funded entities in both therapeutic areas.
The long, capital-intensive development path presents substantial execution risk.

Competitive Landscape

In metabolic disease, FGH competes with numerous biopharma companies developing therapies for NASH and diabetes targeting various pathways (FXR, ACC, GLP-1). In oncology, the competitive field for prostate cancer includes next-generation hormonal agents, PARP inhibitors, and radiopharmaceuticals. FGH's differentiation lies in its novel SREBP-focused mechanism, but it is a late entrant against advanced clinical programs.

More companies in Small Molecule Drugs →More companies in United States →